SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): June 9, 2004
ARIAD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On June 9, 2004, the Registrant disseminated a Press Release
announcing that the telephone number for U.S. investors wishing to
listen to the upcoming analyst conference call to be hosted by the
Company on June 15, 2004 has been revised. The revised telephone
number is 888-482-0024. All other telephone numbers, as well as the
pass code numbers, in today's earlier press release announcing the
analyst conference call remain unchanged.
The information contained in the Press Release dated June 9, 2004, is
incorporated herein by reference and attached as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 9, 2004.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: June 9, 2004
2
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- ---------------------------
99.1 The Registrant's Press Release 4
dated June 9, 2004.
3